Creation of novel large dataset comprising several granulation methods and the prediction of tablet properties from critical material attributes and critical process parameters using regularized linear regression models including interaction terms.


Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
15 Mar 2020
Historique:
received: 12 10 2019
revised: 04 01 2020
accepted: 22 01 2020
pubmed: 29 1 2020
medline: 26 11 2020
entrez: 29 1 2020
Statut: ppublish

Résumé

Our aim was to understand better the causal relationships between material attributes (MAs), process parameters (PPs), and critical quality attributes (CQAs) using an originally created large dataset and regularized linear regression models. In this study, we focused on the following three points: (1) creation of a dataset comprising several tablet production methods, (2) the influence of interaction terms of MAs and/or PPs, and (3) comparison of regularized linear regression models with partial least squares (PLS) regression. First, we prepared 44 kinds of tablets using direct compression and five kinds of granulation methods. We then measured 12 MAs and two model CQAs (tensile strength and disintegration time of tablet). Principal component analysis showed that the constructed dataset comprised a wide variety of particles. We applied regularized linear regression models, such as ridge regression, LASSO and Elastic Net (ENET), and PLS to our dataset to predict CQAs from the MAs and PPs. As a result of external validation, the prediction performance of the models was sufficiently high, although ENET was slightly better than the other methods. Moreover, in almost all cases, the models with interaction terms showed higher predictive ability than those without interaction terms, indicating that the interaction terms of MAs and/or PPs have a strong influence on CQAs. ENET also allowed the selection of critical factors that strongly affect CQAs. The results of this study will help to understand systematically knowledge obtained in pharmaceutical development.

Identifiants

pubmed: 31988032
pii: S0378-5173(20)30067-3
doi: 10.1016/j.ijpharm.2020.119083
pii:
doi:

Substances chimiques

Excipients 0
Tablets 0
Ibuprofen WK2XYI10QM

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

119083

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The authors declare the following competing financial interest(s): The Department of Pharmaceutical Technology, University of Toyama, is an endowed department, supported by an unrestricted grant from Nichi-Iko Pharmaceutical Co (Toyama, Japan).

Auteurs

Takuya Oishi (T)

Department of Pharmaceutical Technology, Graduate School of Medicine and Pharmaceutical Science for Research, University of Toyama, 2630 Sugitani, Toyama-shi, Toyama 930-0194, Japan.

Yoshihiro Hayashi (Y)

Department of Pharmaceutical Technology, Graduate School of Medicine and Pharmaceutical Science for Research, University of Toyama, 2630 Sugitani, Toyama-shi, Toyama 930-0194, Japan; Formulation Development Department, Development & Planning Division, Nichi-Iko Pharmaceutical Co., Ltd., 205-1, Shimoumezawa, Namerikawa-shi, Toyama 936-0857, Japan. Electronic address: yoshihiro-hayashi@nichiiko.co.jp.

Miho Noguchi (M)

Department of Pharmaceutical Technology, Graduate School of Medicine and Pharmaceutical Science for Research, University of Toyama, 2630 Sugitani, Toyama-shi, Toyama 930-0194, Japan.

Fumiaki Yano (F)

Formulation Development Department, Development & Planning Division, Nichi-Iko Pharmaceutical Co., Ltd., 205-1, Shimoumezawa, Namerikawa-shi, Toyama 936-0857, Japan.

Shungo Kumada (S)

Formulation Development Department, Development & Planning Division, Nichi-Iko Pharmaceutical Co., Ltd., 205-1, Shimoumezawa, Namerikawa-shi, Toyama 936-0857, Japan.

Kozo Takayama (K)

Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama 350-0295, Japan.

Kotaro Okada (K)

Department of Pharmaceutical Technology, Graduate School of Medicine and Pharmaceutical Science for Research, University of Toyama, 2630 Sugitani, Toyama-shi, Toyama 930-0194, Japan.

Yoshinori Onuki (Y)

Department of Pharmaceutical Technology, Graduate School of Medicine and Pharmaceutical Science for Research, University of Toyama, 2630 Sugitani, Toyama-shi, Toyama 930-0194, Japan.

Articles similaires

Humans Machine Learning Lymphoma Spectroscopy, Fourier Transform Infrared Female
Electronic Health Records Humans Datasets as Topic
Nanoparticles Needles Polylactic Acid-Polyglycolic Acid Copolymer Polyethylene Glycols Curcumin

Classifications MeSH